share_log

Design Therapeutics Analyst Ratings

Benzinga ·  Nov 15, 2023 00:51
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/14/2023 79.36% RBC Capital $7 → $4 Maintains Sector Perform
08/15/2023 169.05% Wedbush → $6 Downgrades Outperform → Neutral
08/15/2023 169.05% SVB Leerink → $6 Downgrades Outperform → Market Perform
08/15/2023 213.89% RBC Capital $23 → $7 Downgrades Outperform → Sector Perform
05/10/2023 931.34% RBC Capital $24 → $23 Maintains Outperform
05/10/2023 751.98% Wedbush $20 → $19 Maintains Outperform
05/04/2023 Goldman Sachs Upgrades Sell → Neutral
03/15/2023 976.18% RBC Capital → $24 Reiterates → Outperform
12/09/2022 886.5% SVB Leerink $30 → $22 Maintains Outperform
12/08/2022 976.18% RBC Capital $29 → $24 Maintains Outperform
08/09/2022 1065.87% Wedbush $21 → $26 Maintains Outperform
06/10/2022 841.66% Wedbush → $21 Initiates Coverage On → Outperform
05/24/2022 169.05% Goldman Sachs $8 → $6 Maintains Sell
05/10/2022 1245.23% SVB Leerink $36 → $30 Maintains Outperform
05/02/2022 1245.23% RBC Capital → $30 Initiates Coverage On → Outperform
01/19/2022 348.41% Goldman Sachs → $10 Initiates Coverage On → Sell
04/20/2021 1514.28% SVB Leerink → $36 Initiates Coverage On → Outperform
04/20/2021 1155.55% Goldman Sachs → $28 Initiates Coverage On → Neutral
04/20/2021 1783.32% Piper Sandler → $42 Initiates Coverage On → Overweight

What is the target price for Design Therapeutics (DSGN)?

The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on November 14, 2023. The analyst firm set a price target for $4.00 expecting DSGN to rise to within 12 months (a possible 79.36% upside). 10 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Design Therapeutics (DSGN)?

The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics maintained their sector perform rating.

When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

Is the Analyst Rating Design Therapeutics (DSGN) correct?

While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a maintained with a price target of $7.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $2.23, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment